15.06.2025, 1063 Zeichen
Marinomed: Austrian science-based biotech company Marinomed Biotech AG has signed a binding term sheet with a Swiss pharmaceutical company for the development and marketing of Budesolv for the Swiss market. The new partner has been granted exclusive rights to sell and distribute Budesolv under its own brand. The deal includes the final development steps that are necessary for filing the marketing authorization in Switzerland. Marinomed is eligible to receive undisclosed upfront and milestone payments as well as royalties on sales. Marinomed retains all rights outside the territory and has the right to use the dossier compiled for Switzerland outside the territory. Andreas Grassauer, CEO of Marinomed comments: “We are confident that this deal is the first trigger for several other partnerships to come. We are convinced that a registration in Switzerland will enable opportunities in a series of other markets abroad.”
Marinomed Biotech: weekly performance:
(From the 21st Austria weekly https://www.boerse-social.com/21staustria (09/06/2025)
Wiener Börse Party #1074: ATX etwas schwächer, Cyan wird am Börsentag Wien mit uns präsentieren und Sprachmelodie vs. grosse Trauer
BKS
Die börsenotierte BKS Bank mit Sitz in Klagenfurt, Österreich, beschäftigt rund 1.100 Mitarbeiter und betreibt ihr Bank- und Leasinggeschäft in den Ländern Österreich, Slowenien, Kroatien und der Slowakei. Die BKS Bank verfügt zudem über Repräsentanzen in Ungarn und Italien. Mit der Oberbank AG und der Bank für Tirol und Vorarlberg AG bildet die BKS Bank AG die 3 Banken Gruppe.
>> Besuchen Sie 61 weitere Partner auf boerse-social.com/partner